Text Size

Controlled Trial of Valacyclovir in Infectious Mononucleosis

This study has been completed.
Sponsor:
Collaborators:
Minnesota Medical Foundation
Hoffmann-La Roche
Information provided by (Responsible Party):
University of Minnesota - Clinical and Translational Science Institute
ClinicalTrials.gov Identifier:
NCT00274404
First received: January 6, 2006
Last updated: October 26, 2011
Last verified: October 2011
History of Changes

January 6, 2006
October 26, 2011
February 2004
September 2005   (final data collection date for primary outcome measure)
Proportion of subjects who have at least a 100-fold (2log10) drop in the amount of EBV in their oral washes during the 14-day treatment period
Same as current
Complete list of historical versions of study NCT00274404 on ClinicalTrials.gov Archive Site
  • Evaluate the safety and tolerability of valacyclovir
  • Evaluate the quantity of EBV in the oral washings
  • Correlate severity of illness with the amount of virus in the oral and blood compartments
  • Evaluate the areas under the viral load - time curves
Same as current
Not Provided
Not Provided
 
Controlled Trial of Valacyclovir in Infectious Mononucleosis
Randomized Study Assessing the Antiviral Activity and Safety of Valacyclovir in Primary Infectious Mononucleosis

The hypothesis is that an antiviral drug (valacyclovir) will reduce the amount of Epstein-Barr virus (EBV) in the mouths of university students with infectious mononucleosis (mono) while being a safe drug. Because EBV is the cause of mono, it is expected that reduction of the amount of virus could result in faster recovery from the disease.

University of Minnesota students 18 years of age or older who are referred by the Boynton student health service during the first 7 days of infectious mononucleosis are eligible to participate. All of the subjects who enroll will be allowed to complete the study, but only the information from those students who truly have mono due to a primary infection with EBV as determined by laboratory tests will be used for the results. The students will be assigned by chance(randomized)either to receive the antiviral drug valacyclovir at a dosage of a 1 gram tablet every 8 hours for 14 days or no antiviral drug. Nine research clinic visits over 180 days are scheduled for clinical exams, histories, and collection of mouth and blood samples. The amount of EBV in the mouth and blood will be measured by a molecular virology research test called real-time TaqMan polymerase chain reaction. The severity of illness will be evaluated using a scale that measures the degree of physical activity and intensity of symptoms. The safety of the drug will be monitored by periodically checking the blood cell counts, and assessing liver and kidney function among other parameters. Personnel who do the lab work and analyze the data will not know the subjects' study drug assignments so that the data can be collected and analyzed objectively. The study will remain open to enrollment until 20 subjects with laboratory-confirmed primary EBV have been enrolled and followed for at least 2 weeks. The study will end when all subjects complete all scheduled study visits.
Interventional
Phase 1
Phase 2
Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Infectious Mononucleosis
Drug: valacyclovir
Not Provided
Balfour HH, Jr., Hokanson KM, Schacherer RM, Fietzer CM, Schmeling DO, Brundage RC. A controlled trial of valacyclovir in infectious mononucleosis. Presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, December 18, 2005. Abstract V1392

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
September 2005
September 2005   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Clinical diagnosis of infectious mononucleosis with onset no more the 7 days before enrollment; willingness to sign informed consent
  • Willingness to provide blood and oral washing samples at regular intervals
  • Females must have a negative urine pregnancy test and agree to use effective contraception (barrier or hormonal) for the first 30 days of the study if assigned to valacyclovir
  • Corticosteroids are permitted only if prescribed by the subject's primary physisican for treatment of this acute disease

Exclusion Criteria:

  • Previous history of mono
  • Pregnant or breast feeding
  • End-stage renal or liver disease
  • Immunosuppressed due to underlying medical disease and/or immunomodulating medications prior to enrollment
  • Onset of present illness >7 days ago
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00274404
0311M53430
Yes
University of Minnesota - Clinical and Translational Science Institute
University of Minnesota - Clinical and Translational Science Institute
  • Minnesota Medical Foundation
  • Hoffmann-La Roche
Principal Investigator: Henry H Balfour, MD University of Minnesota - Clinical and Translational Science Institute
University of Minnesota - Clinical and Translational Science Institute
October 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP